About Brii Biosciences
Brii Biosciences is a publicly listed company based in San Francisco (United States) founded in 2018 by Zhi Hong. Brii Biosciences has raised $415 million across 3 funding rounds from investors including Arch Venture Partners, Invesco and Lake Bleu Capital. The company has 98 employees. Its chief executive, as recorded, is Zhi Hong. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its competitors include Moderna, Adaptive Biotechnologies and Novavax; 2 of its 3 listed competitors have raised funding.
Company details
Developer of biologics to treat hepatitis B infection. It has clinical programs focused on hepatitis B virus (HBV) infection and immunotherapeutics to treat infectious diseases. It has licensed rights to develop a recombinant protein-based immunotherapeutic (VBI-2601) from VBI Vaccines in China. It is also developing VIR-2218, an investigational RNA interference (RNAi) therapeutics to treat hepatitis B infection (licensed from Vir Biotechnology).
- Headquarters San Francisco, United States
- Employees 98
- Founders Zhi Hong
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website briibio.com
- Social LinkedIn
- Legal Name Brii Biosciences Limited
- Annual Revenue$2.59 M (USD)as on Dec 31, 2025
- Net Profit-$31.02 M (USD)56.18as on Dec 31, 2025
- EBITDA-$41.78 M (USD)32.58as on Dec 31, 2025
- Total Equity Funding$415M (USD)
in 3 rounds
- Latest Funding Round$100M (USD), Post-IPO
Sep 2021
- InvestorsArch Venture Partners
& 8 more
- Employee Count98
Funding Insights of Brii Biosciences
Brii Biosciences has successfully raised a total of $415M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $415M
- Total Rounds 3
- Last Round Post-IPO — $100M
- First Round $260M
(May 2018)
- Investors Count 9
All 3 funding rounds of Brii Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | $100M | Post-IPO | – | – | – |
| Mar 2021 | $155M | Series D | – | Invesco | |
| May 2018 | $260M | Series D | – | Yunfeng Capital, Arch Venture Partners | – |
9 investors in total: 9 institutional.
Investors in Brii Biosciences
Brii Biosciences has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Arch Venture Partners, Invesco and Lake Bleu Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| lakebleu-cap.com | ||||
Sovereign wealth is managed and private equity investments are facilitated. | gic.com.sg | Singapore, Singapore | ||
Private equity investments are managed by Yunfeng Capital in China. | yfc.cn | Shanghai, China | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Life-Sciences focused early and growth stage VC firm funding companies in China & the US | 6dimensionscapital.com | Pudong, China | ||
Boyu Capital is recognized as a leading alternative asset management firm. | boyucapital.com | Hong Kong, China | ||
Diversified asset management services are offered globally by Invesco. | invesco.com | Atlanta, United States | ||
Functions as an investment advisory firm providing expert guidance. | 2004 | bluepoolcapital.com | Hong Kong, China | |
HongShan is engaged in venture capital investments for innovative companies. | hongshan.com | Hong Kong, China |
Investor details for Brii Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Brii Biosciences
40 people are tracked at Brii Biosciences (23 in leadership, 13 in board & advisors, 4 in team); the tracked headcount is 98.
| Name | Role | Group |
|---|---|---|
Zhi Hong | Co-Founder & CEO | Leadership |
Donna Zhang | Senior Director, IT & Data Sciences | Leadership |
Qing Zhu | SVP, Head of Biopharmaceutical Research | Leadership |
Eleanor De Groot | Chief Technology Officer | Leadership |
Aleksandar Skuban | Head, CNS Diseases Therapy Area | Leadership |
Yali Zhu | Senior Director Of Clinical Pharmacology | Leadership |
Ankang Li | Chief Financial & Strategy Officer | Leadership |
David Margolis | VP & Head, Infectious Diseases Therapy Area | Leadership |
Rogers Luo | Executive Director, President & GM, Greater China & CEO, TSB Therapeutics | Leadership |
Karen D. Neuendorff | Chief People Officer & Head of Human Resources | Leadership |
Ellee de Groot | Chief Technology Officer | Leadership |
Amy Zhang | Associate Director，hr&talent Development | Leadership |
Aiyang Tao | Head Of Biostatistics And Programming | Leadership |
Joyce F. | Senior Director, IT & Data Sciences | Leadership |
Lijie Zhong | VP Of Biometrics, Epidemiology, And Real World Evidence | Leadership |
Maya Brannan | Director, Senior HR Business Partner | Leadership |
Peter Chan | Associate Director, IT Data And Sciences | Leadership |
Linlin Ou | Senior Director, Human Resource And Talent Development | Leadership |
Yao Zhang | Executive Director Of Clinical Research | Leadership |
Brian Johns | Chief Scientific Officer | Leadership |
20 more people are available in the full profile.
Complete people profiles for Brii Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Brii Biosciences
Brii Biosciences is a publicly listed company on the HKEX with ticker symbol 2137 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 Jul 2021
- Listed onHKG: 2137
- Listed entityBrii Biosciences Limited
- Exchange sectorHealth technology
- ISINKYG1645A1094
- Share price0.83 HKD (-1.18% on the day) · 2026-10-14
- Market capitalisation610,594,576.00 HKD
- EPS (diluted, trailing year)-0.27 HKD
- Volume (last session)363,250
Financials of Brii Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 20.2M HKD | -241.4M HKD | -325.2M HKD |
| 2024 | -551.0M HKD | -482.4M HKD | |
| 2023 | 681,780 HKD | -193.2M HKD | -645.7M HKD |
| 2022 | 60.0M HKD | -563.2M HKD | -659.9M HKD |
| 2021 | -5.02B HKD | -826.5M HKD |
Detailed financial statements for Brii Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Brii Biosciences
4 dated milestones of Brii Biosciences across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Brii Biosciences is founded.
- Funding First funding round of $260.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $100.0M.
Competitors of Brii Biosciences
Brii Biosciences has 3 listed competitors in our database, 2 of them funded. They include Moderna, Adaptive Biotechnologies and Novavax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| novavax.com | 1987 | Gaithersburg, United States | 184 | Novel vaccines are developed using nanoparticle and matrix adjuvant technology. |
Detailed competitors of Brii Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Brii Biosciences
The website of Brii Biosciences (briibio.com) receives about 3.2K visits a month and ranks #4,166,358 among all websites worldwide, #5,170 in Biotechnology and Pharmaceuticals.
- Monthly visits3.2K
▼ 28.1% vs previous month
- Unique visitors1.9K
per month
- Global rank#4,166,358
among all websites
- Category rank#5,170
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.6
- Average visit11 sec
- DevicesDesktop 29% · Mobile 71%
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Brii Biosciences (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Brii Biosciences
Complete news archive for Brii Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Brii Biosciences
Brii Biosciences was founded in 2018.
Brii Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Zhi Hong is the CEO of Brii Biosciences, as recorded in our data. They have also founded this company.
Brii Biosciences is a funded company, having raised a total of $415M across 3 funding rounds to date. The company's 1st funding round was a Series D of $260M, raised on May 2018.
Brii Biosciences has 98 employees.
Annual revenue of Brii Biosciences is $2.59M as on Dec 31, 2025.
Developer of biologics to treat hepatitis B infection. It has clinical programs focused on hepatitis B virus (HBV) infection and immunotherapeutics to treat infectious diseases. It has licensed rights to develop a recombinant protein-based immunotherapeutic (VBI-2601) from VBI Vaccines in China. It is also developing VIR-2218, an investigational RNA interference (RNAi) therapeutics to treat hepatitis B infection (licensed from Vir Biotechnology).
Brii Biosciences's top competitors include Moderna, Adaptive Biotechnologies and Novavax.
Yes, Brii Biosciences is publicly traded on HKEX under the ticker symbol 2137.
Brii Biosciences has 9 investors. Key investors include Arch Venture Partners, Invesco, Lake Bleu Capital, GIC, and Yunfeng Capital.
Brii Biosciences operates through Brii Biosciences.